Carbon Ion Therapy for Peripheral Non-small Cell Lung Cancer
ConditionNon-small Cell Lung Cancer
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-80
SponsorShanghai Proton and Heavy Ion Center
About this trial
To investigate the efficacy of carbon ion therapy for stage Ia-IIa primary peripheral non-small cell lung cancer (NSCLC). The primary endpoint was progression-free survival (PFS), and the secondary endpoint was local control rate, overall survival (OS) and toxicities.
Eligibility criteria
Qualifiers
Between the ages of 18 and 80.
ECOG general status score of 0-2 .
Primary non-small cell lung cancer (NSCLC) confirmed by histology or cytological pathology, T1-2N0M0, stage Ia-IIa (AJCC/UICC 8th edition).
The location of the tumor belongs to the peripheral type defined in this study (2cm and beyond (≥2cm) from the esophagus, main bronchial tree, spinal cord, heart, great blood vessels, brachial plexus and stomach, and 1cm and beyond (≥1cm) from the chest wall).
Disqualifiers
Multiple primary tumors.
Patient fails to comply with the treatment protocol.
Complicated with other malignant tumors that have not been controlled.
Patient whose particle radiotherapy plan cannot meet the minimum target dose coverage and dose volume limitation requirements, or cannot meet the dose constrains of normal tissue or organs.
Trial design
Treatments tested in this trial
- Carbon ion beam radiotherapy
Treatment groups
43 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov